全文获取类型
收费全文 | 81702篇 |
免费 | 5480篇 |
国内免费 | 704篇 |
专业分类
耳鼻咽喉 | 1259篇 |
儿科学 | 1680篇 |
妇产科学 | 1890篇 |
基础医学 | 11481篇 |
口腔科学 | 1981篇 |
临床医学 | 8137篇 |
内科学 | 17936篇 |
皮肤病学 | 1749篇 |
神经病学 | 7164篇 |
特种医学 | 3376篇 |
外科学 | 10546篇 |
综合类 | 847篇 |
一般理论 | 59篇 |
预防医学 | 4860篇 |
眼科学 | 1724篇 |
药学 | 6157篇 |
1篇 | |
中国医学 | 396篇 |
肿瘤学 | 6643篇 |
出版年
2023年 | 471篇 |
2022年 | 710篇 |
2021年 | 2138篇 |
2020年 | 1240篇 |
2019年 | 1800篇 |
2018年 | 2140篇 |
2017年 | 1751篇 |
2016年 | 2163篇 |
2015年 | 2548篇 |
2014年 | 3196篇 |
2013年 | 4185篇 |
2012年 | 6237篇 |
2011年 | 6499篇 |
2010年 | 3884篇 |
2009年 | 3458篇 |
2008年 | 5135篇 |
2007年 | 5344篇 |
2006年 | 4789篇 |
2005年 | 4782篇 |
2004年 | 4276篇 |
2003年 | 4039篇 |
2002年 | 3691篇 |
2001年 | 1179篇 |
2000年 | 1028篇 |
1999年 | 1114篇 |
1998年 | 807篇 |
1997年 | 685篇 |
1996年 | 604篇 |
1995年 | 517篇 |
1994年 | 454篇 |
1993年 | 405篇 |
1992年 | 539篇 |
1991年 | 458篇 |
1990年 | 470篇 |
1989年 | 477篇 |
1988年 | 438篇 |
1987年 | 369篇 |
1986年 | 354篇 |
1985年 | 371篇 |
1984年 | 321篇 |
1983年 | 277篇 |
1982年 | 270篇 |
1981年 | 230篇 |
1980年 | 208篇 |
1979年 | 236篇 |
1978年 | 204篇 |
1977年 | 197篇 |
1976年 | 138篇 |
1975年 | 166篇 |
1974年 | 133篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
121.
122.
123.
124.
Andrea von Berg Renate Engelstätter Predrag Minic Miodrag Sréckovic Maria Luz Garcia Garcia Tadeusz Lato Jan H. Vermeulen Stefan Leichtl Stefan Hellbardt Thomas D. Bethke 《Pediatric allergy and immunology》2007,18(5):391-400
Ciclesonide is an onsite-activated inhaled corticosteroid (ICS) for the treatment of asthma. This study compared the efficacy, safety and effect on quality of life (QOL) of ciclesonide 160 microg (ex-actuator; nominal dose 200 microg) vs. budesonide 400 microg (nominal dose) in children with asthma. Six hundred and twenty-one children (aged 6-11 yr) with asthma were randomized to receive ciclesonide 160 microg (ex-actuator) once daily (via hydrofluoroalkane metered-dose inhaler and AeroChamber Plus spacer) or budesonide 400 microg once daily (via Turbohaler) both given in the evening for 12 wk. The primary efficacy end-point was change in forced expiratory volume in 1 s (FEV1). Additional measurements included change in daily peak expiratory flow (PEF), change in asthma symptom score sum, change in use of rescue medication, paediatric and caregiver asthma QOL questionnaire [PAQLQ(S) and PACQLQ, respectively] scores, change in body height assessed by stadiometry, change in 24-h urinary cortisol adjusted for creatinine and adverse events. Both ciclesonide and budesonide increased FEV1, morning PEF and PAQLQ(S) and PACQLQ scores, and improved asthma symptom score sums and the need for rescue medication after 12 wk vs. baseline. The non-inferiority of ciclesonide vs. budesonide was demonstrated for the change in FEV1 (95% confidence interval: -75, 10 ml, p = 0.0009, one-sided non-inferiority, per-protocol). In addition, ciclesonide and budesonide showed similar efficacy in improving asthma symptoms, morning PEF, use of rescue medication and QOL. Ciclesonide was superior to budesonide with regard to increases in body height (p = 0.003, two-sided). The effect on the hypothalamic-pituitary-adrenal axis was significantly different in favor of ciclesonide treatment (p < 0.001, one-sided). Both ciclesonide and budesonide were well tolerated. Ciclesonide 160 microg once daily and budesonide 400 microg once daily were effective in children with asthma. In addition, in children treated with ciclesonide there was significantly less reduction in body height and suppression of 24-h urinary cortisol excretion compared with children treated with budesonide after 12 wk. 相似文献
125.
Nan-Fu Chen Yeou-Chih Wang Chiung-Chyi Shen Yee-Jee Jan Wen-Hsien Chen Ching-Hsiang Leu 《Journal of clinical neuroscience》2004,11(5):527-530
We report a case of calcified chronic encapsulated intracerebral haematoma (ICH) in a 29-year-old female who presented with progressive left sided weakness and intermittent seizures since childhood. The preoperative magnetic resonance (MR) imaging of the head initially suggested that a partially thrombosed aneurysm or vascular malformation was present. However, no vascular stain was found on the digital subtraction angiography (DSA) of both the carotid and vertebral arteries. The excised mass was histologically diagnosed as a chronic ICH. We traced the patient's medical history and found that at the age of one she sustained a head injury after a fall. So far, to our knowledge, no case of epilepsy secondary to a calcified chronic encapsulated ICH occurring 28 years after head injury has been reported. Calcified chronic encapsulated ICH concomitant with new bone formation within is even rarer. The possible pathogenesis of this case is discussed. 相似文献
126.
127.
128.
Jong-Moon Lee Kun-Woo Park Woo-Keun Seo Moon Ho Park Changsu Han Inho Jo Sangmee Ahn Jo 《Movement disorders》2007,22(16):2446-2449
There have been a few studies and inconsistent results regarding the coincidence of Parkinson's disease (PD) and atherosclerotic diseases, such as cerebrovascular disease. Carotid intima-media thickness (IMT) is a known marker for subclinical atherosclerosis. The aim of this study was to investigate the carotid IMT between PD patients and controls. We studied 43 patients with PD and 86 matched controls. The carotid IMT in PD patients was significantly smaller than in controls (0.796 +/- 0.179 mm vs. 0.913 +/- 0.237 mm, P < 0.05). In multivariate analysis, the carotid IMT was inversely associated with the duration of levodopa medication and the severity of PD. These results suggest that PD patients have a lower risk of atherosclerosis. 相似文献
129.
Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients 总被引:5,自引:0,他引:5
Chi Yuen Cheung Kim Ming Wong Hoi Wong Chan Yan Lun Liu Yiu Han Chan Ho Sing Wong Wai Leung Chak Koon Shing Choi Ka Foon Chau Chun Sang Li 《Transplant international》2006,19(8):657-666
Few studies used paired kidneys for comparison between tacrolimus and cyclosporine in renal transplantation. Most of the published data used whole blood trough levels for drug monitoring. However, the use of limited sampling strategy and abbreviated formula to estimate the 12-h area under concentration-time curve (AUC(0-12)) allowed better prediction of drug exposure. Sixty-six first cadaveric renal transplant recipients receiving paired kidneys were randomized to receive either tacrolimus-based (n = 33) or cyclosporine microemulsion (Neoral)-based therapies (n = 33). Abbreviated AUC(0-12) was used for drug monitoring and dose titration. Mean follow-up duration was 2.8 +/- 2 years. The patient and graft survival were comparable. Fewer incidence of acute rejection was observed in tacrolimus group (15% vs. 27.3%) though the difference was not significant (P = 0.23). The absolute value and the rate of decline of creatinine clearance were both significantly better in tacrolimus-treated patients. Prevalence of hypertension, post-transplant diabetes mellitus, infection, and malignancy were similar in both groups. Prevalence of hypercholesterolemia (11/33 vs. 4/33) and gum hypertrophy (6/33 vs. 1/33) was more common in cyclosporine-treated patients (P = 0.04 in both parameters). This was the first prospective, randomized study with paired kidney analysis showing the renal function was significantly better in tacrolimus-treated patients than in cyclosporine-treated patients. 相似文献
130.